Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04447703 · ClinicalTrials.gov registry record · NA
Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET Study
A NA study, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- NA
- Development phase
- 346
- Enrollment target
NCT04447703: Completed NA study, sponsored by Thomas Jefferson University.
NCT04447703 is a NA study that has completed, run by Thomas Jefferson University. The registered enrollment target is 346 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04447703, a NA study, has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- NA
- Development phase
- 346 participants
- Enrollment target
Study Summary
This trial performs user testing of a mobile-friendly patient history collection and genetic education tool to improve healthcare providers' understanding of prostate cancer genetic testing. This trial also compares traditional genetic counseling versus a web-based genetic education (WBGE) tool to provide information about genetic testing to men with prostate cancer. The WBGE tool has educational modules on genetic counseling and testing, as well as a patient history collection tool to help providers learn which patients may carry genetic mutations and may be considered for genetic counseling and genetic testing. The purpose of this research is to use technology to deliver information on genetic testing for prostate cancer to patients to help them decide whether or not to receive genetic testing.
Primary Outcome
Provider perspectives will include: (1) whether the target population can use the tool in the way it was intended (i.e., to perform patient history collection to determine consideration for germline testing), and (2) interaction with this tool affects the user's cognitive representation of genetic testing for prostate cancer (PCA). To evaluate the first point, will collect initial information from participants regarding their experience with the guidelines for genetic testing and how they collec
Interventions
- OTHER Survey Administration
- OTHER Interview
- OTHER Genetic Counseling
- GENETIC Genetic Testing
- OTHER Internet Based Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 346 participants |
| Start Date | 2020-08-27 |
| Est. Completion | 2024-09-10 |
| Phase | NA |
What the finished NCT04447703 record still lists
NCT04447703 is an interventional study that assigns participants to a tested intervention. The registered 346 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 5 interventions - of which Survey Administration is the first listed.
NCT04447703 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04447703 about?
NCT04447703 is a clinical study titled "Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET Study". This trial performs user testing of a mobile-friendly patient history collection and genetic education tool to improve healthcare providers' understanding of prostate cancer genetic testing. This trial also compares traditional genetic counseling versus a web-based genetic education (WBGE) tool to p...
What is the current status of trial NCT04447703?
This trial is currently completed. It is a NA study. The enrollment target is 346 participants. The study started on 2020-08-27. Estimated completion is 2024-09-10.
What interventions are being tested in trial NCT04447703?
The interventions under investigation include: Survey Administration (OTHER), Interview (OTHER), Genetic Counseling (OTHER), Genetic Testing (GENETIC), Internet Based Intervention (OTHER).
Who is sponsoring clinical trial NCT04447703?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04447703's enrollment target sits among peer trials
346 302nd of 2000 higher than 1,699 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05267886 · 346 participants · Phase 4
CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock
- NCT06705842 · 346 participants · Phase 4
APPI-Cost Trial for Perforated Appendicitis
- NCT06932887 · 346 participants · Phase 3
The Beat Pain Better Trial
- NCT01742143 · 347 participants
Impact of ICCAN on Cancer Treatment Completion and Quality of Life
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI